Compare WD & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WD | AVLN |
|---|---|---|
| Founded | 1937 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2010 | 2026 |
| Metric | WD | AVLN |
|---|---|---|
| Price | $40.84 | $33.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $76.00 | N/A |
| AVG Volume (30 Days) | ★ 389.0K | 175.5K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $1,234,306,000.00 | N/A |
| Revenue This Year | $20.60 | N/A |
| Revenue Next Year | $7.79 | N/A |
| P/E Ratio | $75.22 | ★ N/A |
| Revenue Growth | ★ 8.99 | N/A |
| 52 Week Low | $39.01 | $24.90 |
| 52 Week High | $90.00 | $40.17 |
| Indicator | WD | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 47.59 |
| Support Level | $39.01 | $34.22 |
| Resistance Level | $52.37 | $40.08 |
| Average True Range (ATR) | 1.22 | 1.96 |
| MACD | 0.39 | -0.39 |
| Stochastic Oscillator | 30.10 | 9.89 |
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of its total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.